- Planetary alignment peaks with celestial show this weekend
- UK fighters escort Pakistan plane to airport, two arrests
- Arizona jury foreman says believed Jodi Arias was abused
- Judge rules against 'America's toughest sheriff' in racial profiling lawsuit
- Justice Department defends journalist email search
Belgium's UCB says 70 mln charge on U.S. exit
BRUSSELS Jan 29 (Reuters) - Belgian pharmaceutical group UCB (UCB.BR) said on Friday its 2009 net profit would be affected by restructuring charges of about 70 million euros ($98.28 million) from its exit from the U.S. primary care market in March.
The group said it was accelerating its U.S. transition to a purely speciality-focused biopharmaceutical company, which would impact net profit.
"These non-recurring charges are expected to reach approximately 70 million euros, lowering UCB's 2009 expected net profit as reported," the company said in a statement.
It said that recurring earnings before interests, taxes, depreciation and amortization (EBITDA) would not be impacted.
The company is scheduled to report its 2009 results on March 3. ($1=.7122 Euro) (Reporting by Bate Felix; editing by Karen Foster)
- Tweet this
- Share this
- Digg this